Investor Presentaiton

B-cell function Investor presentation First three months of 2017 Slide 35 Insulin is the ultimate care for people with diabetes Progression of type 2 diabetes and treatment intensification Distribution of patients and value across treatment classes Diet and exercise OAD: Oral anti-diabetic changing diabetes® Time OAD GLP-1 Insulin GLP-1 100% 80% 37% 68% 60% 9% 40% Insulin 4% 54% 20% 28% 0% Patients Value Note: Patient distribution across treatment classes is indicative and based on data for US, UK, Germany and France. Value figures based on IMS MAT February 2017 Source: IMS PharMetrix claims data, IMS disease analyser, IMS Midas OAD novo nordisk

View entire presentation